0001209191-23-046103.txt : 20230816
0001209191-23-046103.hdr.sgml : 20230816
20230816181159
ACCESSION NUMBER: 0001209191-23-046103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230816
DATE AS OF CHANGE: 20230816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schor Chen
CENTRAL INDEX KEY: 0001340875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 231179354
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-14
0
0001720580
Adicet Bio, Inc.
ACET
0001340875
Schor Chen
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
1
1
0
0
President & CEO
0
Stock Option (Right to Buy)
8.89
2023-08-14
4
D
0
36857
0.00
D
2029-12-05
Common Stock
36857
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
36857
0.00
A
2029-12-05
Common Stock
36857
36857
D
Stock Option (Right to Buy)
16.11
2023-08-14
4
D
0
872111
0.00
D
2030-09-16
Common Stock
872111
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
872111
0.00
A
2030-09-16
Common Stock
872111
872111
D
Stock Option (Right to Buy)
13.27
2023-08-14
4
D
0
240000
0.00
D
2031-01-12
Common Stock
240000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
240000
0.00
A
2031-01-12
Common Stock
240000
240000
D
Stock Option (Right to Buy)
16.82
2023-08-14
4
D
0
421600
0.00
D
2031-02-11
Common Stock
421600
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
421600
0.00
A
2031-02-11
Common Stock
421600
421600
D
Stock Option (Right to Buy)
15.52
2023-08-14
4
D
0
295000
0.00
D
2032-01-06
Common Stock
295000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
295000
0.00
A
2032-01-06
Common Stock
295000
295000
D
Stock Option (Right to Buy)
9.05
2023-08-14
4
D
0
384900
0.00
D
2033-01-23
Common Stock
384900
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
384900
0.00
A
2033-01-23
Common Stock
384900
384900
D
Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020.
On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
The shares subject to this option are fully vested and exercisable as of the date hereof.
The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
/s/ Nick Harvey, Attorney-in-Fact
2023-08-16